BACK TO CBER — Dr. Vinay Prasad has returned to the FDA’s Center for Biologics Evaluation and Research, leaving industry and ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

Duchenne (SGT-003): 15 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial and dosing remains ongoing; On track to ...

Vinay Prasad resumes leadership at the FDA’s CBER two weeks after he resigned amid cell and gene therapy controversy.

Catalyst Pharmaceuticals stock shines with FIRDAPSE & AGAMREE growth. Learn why the biopharma name is cheap enough to start ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

Vor Bio appoints Dallan Murray as chief commercial officer, leveraging his extensive experience to drive commercialization ...

Amyloid-beta exerted a pathogenic effect in cats with dementia, suggesting feline cognitive dysfunction syndrome may be a ...

Quince Therapeutics ( ($QNCX) ) has released its Q2 earnings. Here is a breakdown of the information Quince Therapeutics presented to its ...

A Food and Drug Administration official is getting his job back as the agency’s top vaccine regulator, less than two weeks ...

Daragh Curran, an Irish social media influencer, attended a charity football match recently and suffered a nasty injury when ...